Beximco increases comprehensive net income in Q1 2017, ships second product to US

Beximco Pharmaceuticals last week started the export of Sotalol Hydrochloride, a generic version of the cardiovascular drug Betapace, to the US.

That was Beximco’s second product started to be exported to US, after the launch of Carvedilol in August 2016. The company on Tuesday announced financial results for the quarter ended September 30, 2017. The company has $644,126 total comprehensive income, compared to $514,857 from the same period last year.

According to QuintlesIMS data, the market size for Satalol Hydrochloride in the US is $23 million. The first consignment was delivered on October 29, 2017 and the product will be distributed through the Company’s existing partner in the US.

In June 2015, Beximco Pharma became the first Bangladeshi pharmaceutical company audited and approved by the US Food and Drug Administration (FDA).


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.